儿童乙肝的新认识(英文版）.pptVIP

Lamivudine paediatric phase 3 study (NUC30903) Placebo (n=97) Wk 52 Baseline No treatment (n=63) One year placebo controlled study Two year follow-on study Lamivudine 3 mg/kg (n=191) Lamivudine 3mg/kg HBeAg-ve HBeAg+ve Treatment (n=213) 89% Durability of response at month 36 Sokal E et al. Hepatology. 2006; 43: 225-32. Long term lamivudine therapy for children with HBeAg+ve CHB (2) Virologic response in the treatment arm 21% after 12 + 24 months of Rx (n=133) 30% after 0 + 24 months Rx (n=77) * VR = loss of HBeAg loss and HBV DNA The incidence of YMDD mutati